CoChat

Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens

Open access
Querings, Silvia, Altmüller, Janine, Ansén, Sascha, Zander, Thomas, Seidel, Danila, Gabler, Franziska, Peifer, Martin, Markert, Eva, Stemshorn, Kathryn, Timmermann, Bernd, Saal, Beate, Klose, Stefan, Ernestus, Karen, Scheffler, Matthias, Engel-Riedel, Walburga, Stoelben, Erich, Brambilla, Elisabeth, Wolf, Jürgen, Nürnberg, Peter, Thomas, Roman K. · 2011 · PLoS ONE
Cited by 115

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Treatment of EGFR-mutant non-small cell lung cancer patients with the tyrosine kinase inhibitors erlotinib or gefitinib results in high response rates and prolonged progression-free survival. Despite the development of sensitive mutation detection approaches, a thorough validation of these in a clinical setting has so far been lacking. We performed, in a clinical setting, a systematic validation of dideoxy 'Sanger' sequencing and pyrosequencing against massively parallel sequencing as one of the most sensitive mutation detection technologies available. Mutational annotation of clinical lung tumor samples revealed that of all patients with a confirmed response to EGFR inhibition, only massively parallel sequencing detected all relevant mutations. By contrast, dideoxy sequencing missed four responders and pyrosequencing missed two responders, indicating a dramatic lack of sensitivity of dideoxy sequencing, which is widely applied for this purpose. Furthermore, precise quantification of mutant alleles revealed a low correlation (r(2) = 0.27) of histopathological estimates of tumor content and frequency of mutant alleles, thereby questioning the use of histopathology for stratification of specimens for individual analytical procedures. Our results suggest that enhanced analytical sensitivity is critically required to correctly identify patients responding to EGFR inhibition. More broadly, our results emphasize the need for thorough evaluation of all mutation detection approaches against massively parallel sequencing as a prerequisite for any clinical implementation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0019601

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 115

Metadata

Authors
Querings, S., Altmüller, J., Ansén, S., Zander, T., Seidel, D., Gabler, F., Peifer, M., Markert, E., Stemshorn, K., Timmermann, B., Saal, B., Klose, S., Ernestus, K., Scheffler, M., Engel-Riedel, W., Stoelben, E., Brambilla, E., Wolf, J., Nürnberg, P., & Thomas, R. K.
Venue
PLoS ONE
Published
2011-05-05
Volume
6
Issue
5
Pages
e19601
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2092950092
Cited by
115
References
5
FWCI
16.83
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. https://app.cochat.ai/papers/10.1371/journal.pone.0019601
The paper
Querings, S., Altmüller, J., Ansén, S., Zander, T., Seidel, D., Gabler, F., Peifer, M., Markert, E., Stemshorn, K., Timmermann, B., Saal, B., Klose, S., Ernestus, K., Scheffler, M., Engel-Riedel, W., Stoelben, E., Brambilla, E., Wolf, J., Nürnberg, P., & Thomas, R. K. (2011). Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS ONE. https://doi.org/10.1371/journal.pone.0019601

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.